Literature DB >> 10711359

Characterization of prostanoid receptors mediating inhibition of histamine release from anti-IgE-activated rat peritoneal mast cells.

C L Chan1, R L Jones, H Y Lau.   

Abstract

1. Prostanoid receptors mediating inhibition of anti-IgE induced histamine release from rat peritoneal mast cells have been characterized pharmacologically. PGD2 and the specific DP receptor agonists BW 245C and ZK 118182 were the most potent inhibitors with half-maximal concentrations of 0.26, 0.06 and 0.02 microM respectively. The maximum inhibition attainable was 60-65% with 10(-5) M BW 245C and ZK 118182. 2. Among several EP receptor agonists investigated, only PGE2 and the EP2/EP3 receptor agonist misoprostol induced significant inhibition (46.8 +/- 4.7% at 10(-4) M and 18.7 +/- 6.8% at 10(-5) M respectively). The IP receptor agonists cicaprost and iloprost were both less potent than the DP agonists in inhibiting histamine release (45.2 +/- 3.3% and 35.1 +/- 2.5% inhibition respectively at 10(-5) M), whereas PGF2 alpha and the TP receptor agonist U-46619 were only marginally effective. 3. The EP4/TP receptor antagonist AH 23848 failed to affect the inhibitory actions of PGD2 or PGE2 even at 10(-5) M, whereas the DP/EP1/EP2 receptor antagonist AH 6809 slightly enhanced the effect of PGD2 at 10(-6) M. 4. At concentrations of 3 x 10(-6) to 10(-5) M, the putative DP receptor antagonist ZK 138357 dose-dependently suppressed the inhibitory activities of the DP agonists, PGE2 and cicaprost. The antagonism of ZK 138357 against the DP receptor agonists appeared to be competitive with pA2 values of around six. 5. In conclusion, these data support our earlier proposal that an inhibitory DP receptor is the predominant prostanoid receptor in rat peritoneal mast cell. The properties of this receptor in relation to putative DP receptor subtypes reported in the literature are discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10711359      PMCID: PMC1571858          DOI: 10.1038/sj.bjp.0703072

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  45 in total

1.  A method for the fluorometric assay of histamine in tissues.

Authors:  P A SHORE; A BURKHALTER; V H COHN
Journal:  J Pharmacol Exp Ther       Date:  1959-11       Impact factor: 4.030

2.  Prostaglandins: action on mast cells in vitro.

Authors:  P Albro; R Thomas; L Fishbein
Journal:  Prostaglandins       Date:  1972-02

3.  Dispersed human lung mast cells. Pharmacologic aspects and comparison with human lung tissue fragments.

Authors:  S P Peters; E S Schulman; R P Schleimer; D W MacGlashan; H H Newball; L M Lichtenstein
Journal:  Am Rev Respir Dis       Date:  1982-12

4.  9-deoxy-delta 9-prostaglandin D2, a prostaglandin D2 derivative with potent antineoplastic and weak smooth muscle-contracting activities.

Authors:  M Fukushima; T Kato; K Ota; Y Arai; S Narumiya; O Hayaishi
Journal:  Biochem Biophys Res Commun       Date:  1982-12-15       Impact factor: 3.575

5.  Definition of prostaglandin-sensitive arterial constrictor systems.

Authors:  R L Jones
Journal:  Acta Biol Med Ger       Date:  1978

6.  Prostaglandin E2, prostaglandin I2 and the vascular changes of inflammation.

Authors:  T J Williams
Journal:  Br J Pharmacol       Date:  1979-03       Impact factor: 8.739

7.  9-Deoxy-delta 9, delta 12-13,14-dihydroprostaglandin D2, a metabolite of prostaglandin D2 formed in human plasma.

Authors:  Y Kikawa; S Narumiya; M Fukushima; H Wakatsuka; O Hayaishi
Journal:  Proc Natl Acad Sci U S A       Date:  1984-03       Impact factor: 11.205

8.  Effect of prostaglandin D2 in modulating histamine release from human basophils.

Authors:  S P Peters; A Kagey-Sobotka; D W MacGlashan; L M Lichtenstein
Journal:  J Pharmacol Exp Ther       Date:  1984-02       Impact factor: 4.030

9.  The effects of histamine and prostaglandin D2 on rat mast-cell cyclic AMP and mediator release.

Authors:  S Wescott; M Kaliner
Journal:  J Allergy Clin Immunol       Date:  1981-11       Impact factor: 10.793

10.  Anti-inflammatory effects of prostaglandin E1: in vivo modulation of the formyl peptide chemotactic receptor on the rat neutrophil.

Authors:  J C Fantone; W A Marasco; L J Elgas; P A Ward
Journal:  J Immunol       Date:  1983-04       Impact factor: 5.422

View more
  9 in total

1.  Lubiprostone reverses the inhibitory action of morphine on mucosal secretion in human small intestine.

Authors:  Xiaohong Sun; Xiyu Wang; Guo-Du Wang; Yun Xia; Sumei Liu; Meihua Qu; Bradley J Needleman; Dean J Mikami; W Scott Melvin; Laura M Bohn; Ryuji Ueno; Jackie D Wood
Journal:  Dig Dis Sci       Date:  2010-12-23       Impact factor: 3.199

2.  Prostaglandin E2 activates EP2 receptors to inhibit human lung mast cell degranulation.

Authors:  Linda J Kay; Wilfred W Yeo; Peter T Peachell
Journal:  Br J Pharmacol       Date:  2006-04       Impact factor: 8.739

3.  Bone marrow stromal cells inhibit mast cell function via a COX2-dependent mechanism.

Authors:  J M Brown; K Nemeth; N M Kushnir-Sukhov; D D Metcalfe; E Mezey
Journal:  Clin Exp Allergy       Date:  2011-01-24       Impact factor: 5.018

4.  Shear-induced interleukin-6 synthesis in chondrocytes: roles of E prostanoid (EP) 2 and EP3 in cAMP/protein kinase A- and PI3-K/Akt-dependent NF-kappaB activation.

Authors:  Pu Wang; Fei Zhu; Norman H Lee; Konstantinos Konstantopoulos
Journal:  J Biol Chem       Date:  2010-06-01       Impact factor: 5.157

Review 5.  Prostanoid receptor antagonists: development strategies and therapeutic applications.

Authors:  R L Jones; M A Giembycz; D F Woodward
Journal:  Br J Pharmacol       Date:  2009-07-15       Impact factor: 8.739

6.  Effects of methyl p-hydroxybenzoate (methyl paraben) on Ca2+ concentration and histamine release in rat peritoneal mast cells.

Authors:  Sanae Fukugasako; Shinichi Ito; Yoshimi Ikemoto
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

Review 7.  Prostaglandin D₂ and T(H)2 inflammation in the pathogenesis of bronchial asthma.

Authors:  Masafumi Arima; Takeshi Fukuda
Journal:  Korean J Intern Med       Date:  2011-03-02       Impact factor: 2.884

8.  Prostaglandin E2 prevents hyperosmolar-induced human mast cell activation through prostanoid receptors EP2 and EP4.

Authors:  Ivonne Torres-Atencio; Erola Ainsua-Enrich; Fernando de Mora; César Picado; Margarita Martín
Journal:  PLoS One       Date:  2014-10-20       Impact factor: 3.240

9.  Mast cells and the liver aging process.

Authors:  Fabio Grizzi; Maurizio Chiriva-Internati; Giuseppe Di Caro; Luigi Laghi; Paul Hermonat; Paolo Mazzola; Diane D Nguyen; Saba Radhi; Jose A Figueroa; Everardo Cobos; Giorgio Annoni
Journal:  Immun Ageing       Date:  2013-03-07       Impact factor: 6.400

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.